Show simple item record

dc.contributor.authorShewmon, David A.
dc.contributor.authorStock, John L.
dc.contributor.authorAbusamra, Lynda C.
dc.contributor.authorKristan, Mary A.
dc.contributor.authorBaker, Stephen P.
dc.contributor.authorHeiniluoma, Kathleen M.
dc.date2022-08-11T08:09:11.000
dc.date.accessioned2022-08-23T16:20:36Z
dc.date.available2022-08-23T16:20:36Z
dc.date.issued1994-05-01
dc.date.submitted2008-05-12
dc.identifier.citationMetabolism. 1994 May;43(5):531-2.
dc.identifier.issn0026-0495 (Print)
dc.identifier.pmid8177039
dc.identifier.urihttp://hdl.handle.net/20.500.14038/35318
dc.description.abstractAn elevated concentration of lipoprotein(a) [Lp(a)] is a potent risk factor for coronary atherosclerosis. Recently, several hormonal agents including estrogen have been reported to decrease serum Lp(a) concentrations. We found that the antiestrogen tamoxifen also decreased Lp(a) concentrations approximately 40% in six patients with breast cancer, an effect that was achieved by 1 month of therapy and that was stable in five of six patients. If the Lp(a)-lowering effect of tamoxifen can be replicated in women without breast cancer, tamoxifen might be considered as an alternative to niacin for the treatment of elevated Lp(a) levels.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8177039&dopt=Abstract ">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/0026-0495(94)90190-2
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectLipids
dc.subjectLipoprotein(a)
dc.subjectMiddle Aged
dc.subjectTamoxifen
dc.subjectTime Factors
dc.subjectCancer Biology
dc.subjectEndocrine System Diseases
dc.titleTamoxifen decreases lipoprotein (a) in patients with breast cancer
dc.typeJournal Article
dc.source.journaltitleMetabolism: clinical and experimental
dc.source.volume43
dc.source.issue5
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infoservices/64
dc.identifier.contextkey507546
html.description.abstract<p>An elevated concentration of lipoprotein(a) [Lp(a)] is a potent risk factor for coronary atherosclerosis. Recently, several hormonal agents including estrogen have been reported to decrease serum Lp(a) concentrations. We found that the antiestrogen tamoxifen also decreased Lp(a) concentrations approximately 40% in six patients with breast cancer, an effect that was achieved by 1 month of therapy and that was stable in five of six patients. If the Lp(a)-lowering effect of tamoxifen can be replicated in women without breast cancer, tamoxifen might be considered as an alternative to niacin for the treatment of elevated Lp(a) levels.</p>
dc.identifier.submissionpathinfoservices/64
dc.contributor.departmentDiabetes and Endocrinology Research Center
dc.contributor.departmentDepartment of Cell Biology
dc.contributor.departmentInformation Services, Academic Computing Services
dc.source.pages531-2


This item appears in the following Collection(s)

Show simple item record